Approved (FDA / EMA)
FDA (U.S.): Approved: Mounjaro (May 13, 2022) for type 2 diabetes; Zepbound (Nov 8, 2023) for chronic weight management in adults with obesity or overweight with a comorbidity, and (Dec 20, 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity.
EMA (EU): Approved: Mounjaro (Sep 15, 2022) for type 2 diabetes (adults and children ≥10 years), later expanded to weight management in adults with BMI ≥30 or ≥27 with a comorbidity.
Women lose on average more weight than men with tirzepatide and semaglutide (2025 review). Tirzepatide may reduce the efficacy of oral contraceptives (delays gastric emptying): switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase is recommended (Lilly information / FDA label). Not used in pregnancy. View the study →
There is no established standard dose for this case; it is advisable to consult a professional.
Phase 3 trial (1,879 patients): tirzepatide (GIP/GLP-1 dual agonist) outperformed semaglutide in lowering HbA1c and weight in type 2 diabetes. One of the most potent metabolic drugs; prescription.
View the study (study) →Drug · Highest evidence: Very high · 1 finding
⚠️ Prescription drug (injectable).
Information, not medical advice. Prescription drugs require a doctor.
Information, not medical advice. Scientific evidence reflects the quality of the studies.